In the last two decades, cardiomyopathy diagnoses in Sweden have skyrocketed, doubling from 2004 to 2023—talk about a startling trend! It’s almost like cardiomyopathy decided to have a party, and everyone’s invited. The rise is most prominent in dilated and hypertrophic cardiomyopathy. But wait, it gets more interesting! There’s been a marked uptick in other types, especially among women, thanks to heightened awareness of Takotsubo syndrome. Who knew broken hearts could be so literal?
Cardiomyopathy cases in Sweden have doubled since 2004, with women seeing a surge in Takotsubo syndrome awareness.
According to a study led by Daniel Lindholm from Norrtälje Hospital, over 57,000 adult patients now feature in national registers. That’s a staggering number. This extensive mapping relied on health registers and mortality data from the National Board of Health and Welfare. The findings? They’re a bit grim. Cardiomyopathy comes with substantial excess mortality. The one-year all-cause mortality for heart failure sits at a chilling 24% and climbs to 58% after five years. Talk about a ticking time bomb! Additionally, the study highlights a substantial increase in cardiomyopathy diagnoses over the last two decades, emphasizing the need for urgent action.
The study also sheds light on heart failure phenotypes. Among the SwedeHF registrations, 57% were categorized as HFrEF, while 20% fit into the HFpEF group. The prevalence of heart failure in Scandinavia is around 2%, and it only seems to get worse with age. It’s a grim reality, especially when considering that higher mortality rates appear for patients without conclusive echocardiography. Not ideal.
And then there are the management practices. A survey of 828 Swedish physicians revealed that while 86% recommend ICD implantation, many are dragging their feet on screening for iron deficiency. Less than 30% of heart failure patients get screened yearly. What’s that about? It’s a game of catch-up when it should be a proactive approach.
